PremiumThe FlyCogent Biosciences price target lowered to $7 from $8 at Baird Cogent Biosciences Advances with Promising Clinical Trials Cogent Biosciences reports Q1 net loss $72M PremiumThe FlyCoinbase initiated, Block upgraded: Wall Street’s top analyst calls Wolfe Research starts Blueprint Medicines at Outperform on bullish Ayvakit view Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls PremiumThe FlyCogent Biosciences price target lowered to $8 from $10 at Baird Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating Cogent Biosciences: Promising Pipeline and Market Opportunities Justify Buy Rating 
